Amyloidosis News and Research

RSS

Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.

Novel gene editing therapy reduces circulating TTR protein levels in patients with ATTR amyloid cardiomyopathy

A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly reduced circulating transthyretin (TTR) protein levels in patients with ATTR amyloid cardiomyopathy, a progressive and fatal cause of heart failure, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2022.

7 Nov 2022

UC San Diego Health first to offer new injectable medication to patients with hereditary transthyretin amyloidosis

UC San Diego Health is first in the nation to offer a new injectable medication to patients with nerve damage caused by hereditary transthyretin amyloidosis, a rare disease that can be fatal without management.

18 Aug 2022

Stem cell transplantation produces prolonged survival with improved safety in patients with AL amyloidosis

AL amyloidosis is a life-threatening disease related to bone marrow cancer, multiple myeloma. It is caused when a person's antibody-producing white blood cells (i.e. plasma cells) do not function properly and generate abnormal protein which misfolds to form amyloid fibrils and deposits made of components of antibodies called light chains, which then deposit in various organs of the body.

14 Jul 2022

New near-infrared probe may aid in early diagnosis of Alzheimer's disease

Inside the body, some seemingly harmless proteins have sinister potential. In the case of Alzheimer's disease, the amyloid-beta (Aβ) protein, which is vital for brain growth, can become tainted and destroy cells, which leads to forgetfulness and memory loss.

14 Jun 2022

Most blood tests to detect Alzheimer’s disease perform inconsistently across racial groups

Three experimental blood tests used to identify people in early stages of Alzheimer's disease perform differently in Black individuals compared to white individuals, according to a new study from Washington University School of Medicine in St. Louis.

21 Apr 2022

Recent advances in non-viral nano-vector delivery of CRISPR/Cas9 genome editing payloads

Researchers reviewed non-viral nano-vectors used for delivering the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated genome editing system.

14 Apr 2022

Study to examine the risks for brain disorders from repetitive head impacts in contact sports

Internationally-renowned researchers from Boston University and the University of California, San Francisco) are launching a new study, called the Head Impact & Trauma Surveillance Study (HITSS).

7 Mar 2022

Researchers reveal unique signature of genes expressed by hematopoietic stem cells

Hematopoietic stem cells (HSCs) have the capacity to both self-renew and differentiate into all mature blood cell types, making them promising treatments for a variety of diseases.

2 Mar 2022

Novel AI tool can spot difficult-to-diagnose cardiac conditions

Physician-scientists in the Smidt Heart Institute at Cedars-Sinai have created an artificial intelligence (AI) tool that can effectively identify and distinguish between two life-threatening heart conditions that are often easy to miss: hypertrophic cardiomyopathy and cardiac amyloidosis.

23 Feb 2022

Understanding SARS-CoV-2-induced systemic amyloidosis

A new study proposed that inflammation combined with aggregates of amyloidogenic peptides of SARS-CoV-2 S proteins might induce systemic amyloidosis.

21 Dec 2021

Deletion of ABI3 gene in the brain may increase risk of developing Alzheimer’s disease

When immune cells move throughout the brain, they act as the first line of defense against viruses, toxic materials and damaged neurons, rushing over to clear out them.

7 Nov 2021

NYU Tandon describes novel peptide with broad therapeutic potential to combat multiple diseases

NYU Tandon professors Mary Cowman and Jin Ryoun Kim recently published a paper describing a novel peptide with broad therapeutic potential to combat chronic inflammation in multiple diseases.

28 Aug 2021

New study reveals how heparan sulfate promotes amyloid deposition in various organs

Amyloid diseases, including Alzheimer's, Parkinson's, type-2 diabetes and other life-threatening diseases, involve pathologic deposits of normally soluble proteins or peptides as insoluble amyloid fibrils. When this happens in vital organs, such as the brain, kidney, liver and heart, it causes organ damage and, if left untreated, death. Unfortunately, the available treatment options are very limited.

29 Jun 2021

Can SARS-CoV-2 trigger amyloidosis?

A new study, released as a preprint on the bioRxiv* server, describes the results of an analysis of the role played by the virus in amyloid formation, with its subsequent effects on the health of various organs and of the whole organism.

21 May 2021

Global spread of COVID-19 has raised serious concern for patients with transthyretin amyloidosis

The global spread of COVID-19 has raised serious concern for patients with chronic disease. A correlation has been identified between the severity of COVID-19 and a patient's preexisting comorbidities.

7 May 2021

Researchers are testing wearable devices to detect early Alzheimer's, other neurodegenerative diseases

The development of a wearable to detect early Alzheimer's and other neurodegenerative diseases years before symptoms show has taken a step closer to reality today, as UK charity Alzheimer's Research UK announces a partnership with Boston University that will see the first digital data flowing into its global Early Detection of Neurodegenerative diseases (EDoN) initiative.

25 Mar 2021

Study: Early benefit assessment of new drugs within the framework of AM-NOG procedure

"The AMNOG procedure has passed its first practical test. It is practicable and can also be implemented in detail", emphasized IQWiG's Director Jürgen Windeler in October 2011, when the Institute had published its first early benefit assessment within the framework of the AM-NOG procedure (AMNOG = Act on the Reform of the Market for Medicinal Products).

22 Mar 2021

UTHSC professor awarded $1.79 million grant to develop new amyloidosis treatment

The National Institute of Diabetes and Digestive and Kidney Diseases recently awarded Jonathan Wall, PhD, professor in the University of Tennessee Health Science Center's Graduate School of Medicine in Knoxville, a $1.79 million grant for his study titled "Developing a Theranostic Immunotherapy for Systemic Amyloidosis."

16 Mar 2021

Study demonstrates the novel agonistic effect of curcumin on lipid transcription

Curcumin is a polyphenol compound produced by plants of the Curcuma longa species and has been reported to have many physiological activities, which include anti-oxidation, anti-inflammatory, anti-cancer, and anti-amyloid properties.

27 Feb 2021

Study: Link between protein folding and misfolding can lead to the formation of amyloid fibers

Researchers from Osaka University have described the link between accurate protein folding and misfolding that can lead to the formation of amyloid fibers, which are implicated in neurodegenerative diseases

31 Jan 2021